- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 28,400 | 0,00 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
05.06.2026 / 12:45 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| EYEPOINT | 9,900 | +0,51 % | EyePoint, Inc.: EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data | - LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after - - Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously... ► Artikel lesen | |
| AMARIN | 11,900 | -3,25 % | U.S. Supreme Court Ends Amarin Patent Fight, Hikma Prevails | LONDON (dpa-AFX) - The United States Supreme Court has ruled in favor of Hikma Pharmaceuticals PLC (HIK.L
HKMPY) and its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., effectively... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 7,160 | +3,17 % | Sellas Life Sciences: 28,7 Mio. US-Dollar aus Optionsscheinausübung stärken Bilanz | ||
| MADRIGAL PHARMACEUTICALS | 409,70 | +1,09 % | Madrigal Pharmaceuticals-Aktie: Wird Rezdiffra zum Mega-Blockbuster? | Die Aktie von Madrigal Pharmaceuticals zählt zu den auffälligsten Gewinnern im Biotech-Sektor der vergangenen Jahre. Entscheidend für die weitere Entwicklung ist die Frage, ob sich das Unternehmen mit... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,100 | -0,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 71,00 | +1,43 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance | Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin- Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product | Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen | |
| DOGECOIN CASH | - | - | Dogecoin Cash, Inc. (OTCQB: DOGP) Announces Development Initiative for "Dogecoin Gold" Digital Asset Framework | MESQUITE, NV, April 17, 2026 (GLOBE NEWSWIRE) -- Dogecoin Cash, Inc. (OTCQB: DOGP) ("DOGP" or the "Company") today announced it is advancing the development of "Dogecoin Gold," a proposed blockchain-based... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | BLUM HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| THERIVA BIOLOGICS | 0,267 | +0,26 % | Theriva Biologics, Inc. - 8-K, Current Report | ||
| BMP PHARMA TRADING | 6,600 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: Konzern weiterhin auf Rekordkurs - B.M.P. Pharma Trading AG erzielt abermals ein sehr gutes Jahresergebnis im Geschäftsjahr 2025 | DJ PTA-News: B.M.P. Pharma Trading AG: Konzern weiterhin auf Rekordkurs - B.M.P. Pharma Trading AG erzielt abermals ein sehr gutes Jahresergebnis im Geschäftsjahr 2025
Unternehmensmitteilung... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 11,400 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,094 | 0,00 % | Allergy Therapeutics - Interim Results for six months ended 31 Dec 2025 | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
Das Unternehmen MERUS LABS INTERNATIONAL INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.